Aprea Therapeutics (APRE) Total Liabilities (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Total Liabilities of $47.6 million for Q1 2026, up 135.45% year-over-year from $20.2 million in Q1 2025, and up 198.82% quarter-over-quarter from $15.9 million in Q4 2025.
Aprea Therapeutics (APRE) Total Liabilities (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Total Liabilities for 9 consecutive years, with $47.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 135.45% year-over-year to $47.6 million; the TTM figure through Mar 2026 stood at $47.6 million (up 135.45% YoY), while the FY2025 annual figure was $15.9 million, down 33.55% from the prior year.
- Total Liabilities climbed to $47.6 million in Q1 2026 per APRE's latest filing, from $15.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $47.6 million in Q1 2026 and bottomed at $3.2 million in Q4 2022.
- Historically, Total Liabilities has averaged $18.1 million across 5 years, with a median of $17.3 million in 2025.
- Annual changes were most pronounced in 2022 — Total Liabilities slumped 56.25% — and 2024, when it soared 685.36%.
- Aprea Therapeutics' Total Liabilities stood at $3.2 million in 2022, then surged by 607.58% to $22.7 million in 2023, then climbed by 5.87% to $24.0 million in 2024, then plunged by 33.55% to $15.9 million in 2025, then jumped by 198.82% to $47.6 million in 2026.
- Business Quant data shows APRE's Total Liabilities at $47.6 million in Q1 2026, $15.9 million in Q4 2025, and $14.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Aprea Therapeutics | 34.28 Mn | 34.28 Mn | - | 42.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.29 Mn |
| Mar 31, 2026 | 47.61 Mn |
| Dec 31, 2025 | 15.93 Mn |
| Sep 30, 2025 | 14.32 Mn |
| Jun 30, 2025 | 17.31 Mn |
| Mar 31, 2025 | 20.22 Mn |
| Dec 31, 2024 | 23.98 Mn |
| Sep 30, 2024 | 26.89 Mn |
| Jun 30, 2024 | 29.96 Mn |
| Mar 31, 2024 | 33.20 Mn |
| Dec 31, 2023 | 22.65 Mn |
| Sep 30, 2023 | 25.77 Mn |
| Jun 30, 2023 | 3.95 Mn |
| Mar 31, 2023 | 4.23 Mn |
| Dec 31, 2022 | 3.20 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 7.68 Mn |
| Mar 31, 2022 | 6.75 Mn |
| Dec 31, 2021 | 7.32 Mn |
| Sep 30, 2021 | 9.07 Mn |